Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAnti depressant escitalopram

    Anti Depressant Escitalopram

    Jump to
    • FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

      FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

      Rajesh Garg, global chief financial officer, Cipla, told CNBC-TV18 that operating profits were impacted in the absence of anti-depressant Escitalopram sales in the US, and higher sales of anti-retroviral (ARV) drugs, where profit margins are low.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347